These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
517 related articles for article (PubMed ID: 27120156)
21. Vaccine-based, long-term, stable control of simian/human immunodeficiency virus 89.6PD replication in rhesus macaques. Yamamoto H; Kawada M; Tsukamoto T; Takeda A; Igarashi H; Miyazawa M; Naruse T; Yasunami M; Kimura A; Matano T J Gen Virol; 2007 Feb; 88(Pt 2):652-659. PubMed ID: 17251584 [TBL] [Abstract][Full Text] [Related]
22. Protective effect of vaginal application of neutralizing and nonneutralizing inhibitory antibodies against vaginal SHIV challenge in macaques. Moog C; Dereuddre-Bosquet N; Teillaud JL; Biedma ME; Holl V; Van Ham G; Heyndrickx L; Van Dorsselaer A; Katinger D; Vcelar B; Zolla-Pazner S; Mangeot I; Kelly C; Shattock RJ; Le Grand R Mucosal Immunol; 2014 Jan; 7(1):46-56. PubMed ID: 23591718 [TBL] [Abstract][Full Text] [Related]
23. Development of Broadly Neutralizing Antibodies and Their Mapping by Monomeric gp120 in Human Immunodeficiency Virus Type 1-Infected Humans and Simian-Human Immunodeficiency Virus SHIVSF162P3N-Infected Macaques. Jia M; Lu H; Markowitz M; Cheng-Mayer C; Wu X J Virol; 2016 Apr; 90(8):4017-4031. PubMed ID: 26842476 [TBL] [Abstract][Full Text] [Related]
25. Protection of Newborn Macaques by Plant-Derived HIV Broadly Neutralizing Antibodies: a Model for Passive Immunotherapy during Breastfeeding. Rosenberg YJ; Jiang X; Cheever T; Coulter FJ; Pandey S; Sack M; Mao L; Urban L; Lees J; Fischer M; Smedley J; Sidener H; Stanton J; Haigwood NL J Virol; 2021 Aug; 95(18):e0026821. PubMed ID: 34190597 [TBL] [Abstract][Full Text] [Related]
26. Protective effects of nef-deleted SHIV or that having IFN-gamma against disease induced with a pathogenic virus early after vaccination. Enose Y; Kita M; Yamamoto T; Suzuki H; Miyake A; Horiuchi R; Ibuki K; Kaneyasu K; Kuwata T; Takahashi E; Sakai K; Shinohara K; Miura T; Hayami M Arch Virol; 2004 Sep; 149(9):1705-20. PubMed ID: 15593414 [TBL] [Abstract][Full Text] [Related]
27. Immunoprofiling Correlates of Protection Against SHIV Infection in Adjuvanted HIV-1 Pox-Protein Vaccinated Rhesus Macaques. Lu P; Guerin DJ; Lin S; Chaudhury S; Ackerman ME; Bolton DL; Wallqvist A Front Immunol; 2021; 12():625030. PubMed ID: 34046030 [TBL] [Abstract][Full Text] [Related]
28. Protection of macaques against vaginal transmission of a pathogenic HIV-1/SIV chimeric virus by passive infusion of neutralizing antibodies. Mascola JR; Stiegler G; VanCott TC; Katinger H; Carpenter CB; Hanson CE; Beary H; Hayes D; Frankel SS; Birx DL; Lewis MG Nat Med; 2000 Feb; 6(2):207-10. PubMed ID: 10655111 [TBL] [Abstract][Full Text] [Related]
29. Passive transfer of modest titers of potent and broadly neutralizing anti-HIV monoclonal antibodies block SHIV infection in macaques. Shingai M; Donau OK; Plishka RJ; Buckler-White A; Mascola JR; Nabel GJ; Nason MC; Montefiori D; Moldt B; Poignard P; Diskin R; Bjorkman PJ; Eckhaus MA; Klein F; Mouquet H; Cetrulo Lorenzi JC; Gazumyan A; Burton DR; Nussenzweig MC; Martin MA; Nishimura Y J Exp Med; 2014 Sep; 211(10):2061-74. PubMed ID: 25155019 [TBL] [Abstract][Full Text] [Related]
30. Limited impact of passive non-neutralizing antibody immunization in acute SIV infection on viremia control in rhesus macaques. Nakane T; Nomura T; Shi S; Nakamura M; Naruse TK; Kimura A; Matano T; Yamamoto H PLoS One; 2013; 8(9):e73453. PubMed ID: 24039947 [TBL] [Abstract][Full Text] [Related]
31. Introduction of the YTE mutation into the non-immunogenic HIV bnAb PGT121 induces anti-drug antibodies in macaques. Rosenberg YJ; Lewis GK; Montefiori DC; LaBranche CC; Lewis MG; Urban LA; Lees JP; Mao L; Jiang X PLoS One; 2019; 14(2):e0212649. PubMed ID: 30785963 [TBL] [Abstract][Full Text] [Related]
32. Vaccination of rhesus macaques with recombinant Mycobacterium bovis bacillus Calmette-Guérin Env V3 elicits neutralizing antibody-mediated protection against simian-human immunodeficiency virus with a homologous but not a heterologous V3 motif. Someya K; Cecilia D; Ami Y; Nakasone T; Matsuo K; Burda S; Yamamoto H; Yoshino N; Kaizu M; Ando S; Okuda K; Zolla-Pazner S; Yamazaki S; Yamamoto N; Honda M J Virol; 2005 Feb; 79(3):1452-62. PubMed ID: 15650171 [TBL] [Abstract][Full Text] [Related]
33. Protection against chronic infection and AIDS by an HIV envelope peptide-cocktail vaccine in a pathogenic SHIV-rhesus model. Nehete PN; Chitta S; Hossain MM; Hill L; Bernacky BJ; Baze W; Arlinghaus RB; Sastry KJ Vaccine; 2001 Dec; 20(5-6):813-25. PubMed ID: 11738745 [TBL] [Abstract][Full Text] [Related]
34. Broadly neutralizing antibody-mediated protection of macaques against repeated intravenous exposures to simian-human immunodeficiency virus. Garber DA; Guenthner P; Mitchell J; Ellis S; Gazumyan A; Nason M; Seaman MS; McNicholl JM; Nussenzweig MC; Heneine W AIDS; 2021 Aug; 35(10):1567-1574. PubMed ID: 33966028 [TBL] [Abstract][Full Text] [Related]
35. Relationship between Vaccine-Induced Antibody Capture of Infectious Virus and Infection Outcomes following Repeated Low-Dose Rectal Challenges with Simian Immunodeficiency Virus SIVmac251. Gach JS; Venzon D; Vaccari M; Keele BF; Franchini G; Forthal DN J Virol; 2016 Oct; 90(19):8487-95. PubMed ID: 27440881 [TBL] [Abstract][Full Text] [Related]
36. Antibody responses elicited in macaques immunized with human immunodeficiency virus type 1 (HIV-1) SF162-derived gp140 envelope immunogens: comparison with those elicited during homologous simian/human immunodeficiency virus SHIVSF162P4 and heterologous HIV-1 infection. Derby NR; Kraft Z; Kan E; Crooks ET; Barnett SW; Srivastava IK; Binley JM; Stamatatos L J Virol; 2006 Sep; 80(17):8745-62. PubMed ID: 16912322 [TBL] [Abstract][Full Text] [Related]
37. Immunological and virological mechanisms of vaccine-mediated protection against SIV and HIV. Roederer M; Keele BF; Schmidt SD; Mason RD; Welles HC; Fischer W; Labranche C; Foulds KE; Louder MK; Yang ZY; Todd JP; Buzby AP; Mach LV; Shen L; Seaton KE; Ward BM; Bailer RT; Gottardo R; Gu W; Ferrari G; Alam SM; Denny TN; Montefiori DC; Tomaras GD; Korber BT; Nason MC; Seder RA; Koup RA; Letvin NL; Rao SS; Nabel GJ; Mascola JR Nature; 2014 Jan; 505(7484):502-8. PubMed ID: 24352234 [TBL] [Abstract][Full Text] [Related]
38. Immunization with HIV-1 SF162-derived Envelope gp140 proteins does not protect macaques from heterologous simian-human immunodeficiency virus SHIV89.6P infection. Xu R; Srivastava IK; Kuller L; Zarkikh I; Kraft Z; Fagrouch Z; Letvin NL; Heeney JL; Barnett SW; Stamatatos L Virology; 2006 Jun; 349(2):276-89. PubMed ID: 16527321 [TBL] [Abstract][Full Text] [Related]
39. HIV-1 vaccines based on replication-competent Tiantan vaccinia protected Chinese rhesus macaques from simian HIV infection. Liu Q; Li Y; Luo Z; Yang G; Liu Y; Liu Y; Sun M; Dai J; Li Q; Qin C; Shao Y AIDS; 2015 Mar; 29(6):649-58. PubMed ID: 25849828 [TBL] [Abstract][Full Text] [Related]